LifeCell International Unlisted Share

Snapshot

LifeCell, founded in 2004, focuses on stem cell and tissue storage, genetic screening, and cell-based therapeutics. By integrating cellular sciences with traditional knowledge, the company offers innovative healthcare solutions and continues to develop products that address both current and future medical needs.

Product Portfolio

• Health Bank: Offers long-term stem cell storage and preservation solutions, including BabyCord 75 Years (₹63,551) for lifetime storage and SpermVault - One Baby (₹11,864) for sperm banking.
• Health Check: Provides comprehensive health screening options, such as Ayushman Maximum (₹2,399) for vital organs and FertiScore (₹7,599) for reproductive health.
• Health Clinic: Features advanced treatments and care products like AmnioPlast THICK™ for ocular wounds and MesoCel for Covid-19 cell-based therapy.

Merger

• In 2022, MFine merged with LifeCell’s diagnostics division to form a new entity, LifeWell. MFine faced financial issues and significant layoffs, having previously raised $97 Mn.
• Investment Details: LifeWell secured $80 Mn in investment from OrbiMed.
• Previous Financials: MFine was valued at $450 Mn-$500 Mn before the merger. LifeCell’s diagnostics and MFine together had over 6 Mn users, with plans to reach 50 Mn in four years.

Initiatives

Flexible Financing for Stem Cell Banking

• Partnership: Collaborating with Bajaj Finserv and LiquiLoans.
• EMI Plans: Zero-interest options with down payments as low as INR 1.
• Buy Now Pay Later: Pay only three out of six EMIs, starting from the fourth month, with processing fees in the first three months.
• Accessibility: Aims to make stem cell banking more affordable and convenient.
• Hybrid Banking Model: Adheres to Indian Paediatric Association’s recommendations with a large stem cell repository and advanced genomic profiling for safety.

Certifications

• Association for the Advancement of Blood & Biotherapies (AABB)
• Information Security Management Certification
• ICCBBA ISBT 128 Standard Compliance
• USFDA Registration and more

Management

Abhaya Kumar Jain | Chairman

• Experience: Entrepreneur with ventures in healthcare, animation, manufacturing, BPO, women’s education, and cremation services, managing multiple enterprises simultaneously.

Mayur Abhaya Jain | Managing Director

• Experience: Biotechnology expert with a focus on scientific innovation, pharmaceuticals, and Six Sigma, driving high-quality standards and disruptive market offerings at LifeCell.

Sumanth Sarangapani | CEO

• Education: Certified Lead Auditor QMS, ISMS NABL lead assessor, and trained in Leadership & High-Performance Organizations by IIM.
• Experience: 14 years at LifeCell managing Supply Chain, Customer Service, and Business Process Automation; skilled in delivering new products and services efficiently.

Financial Snapshot

All Values are in INR Cr.

Key Takeaways:

• Revenue has increased by almost 25% in FY23 indicative of positive prospects.
• EBITDA is positive in FY23 after a loss making run.
• PAT has increased exponentially over the financial year, owing to a large contribution by exceptional items.

Peer Comparison

All values are in INR Cr for FY23.

Funding

• Capital Raised: ₹255 crore from OrbiMed (₹225 crore) and existing founders (₹30 crore).
• Usage: To support growth, expansion into new categories, and storage divisions.
• Advisors: Ernst & Young LLP (investment banking) and LKS (legal).
• Board Update: Sunny Sharma of OrbiMed Asia to join LifeCell’s Board.
• Growth: Aims for high double-digit revenue growth, with past revenue at ₹234 crore and increased focus on biological division.

LifeCell has raised a total funding of $61.2 million across five rounds, signifying its substantial backing from investors over the years

Life Cell Annual Report  2020-21